Check for updates

OPEN ACCESS

EDITED BY Marta Araujo-Castro, Ramón y Cajal University Hospital, Spain

REVIEWED BY Giovanni Cochetti, University of Perugia, Italy Tao Zhennan, Nanjing Drum Tower Hospital, China

*CORRESPONDENCE Yucheng Xie Xieyucheng@etyy.cn

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 23 April 2023 ACCEPTED 31 July 2023 PUBLISHED 23 August 2023

CITATION

Zhanghuang C, Long N, Yang Z and Xie Y (2023) Bilateral adrenal giant medullary lipoma combined with disorders of sex development: a rare case report and literature review. *Front. Oncol.* 13:1210679. doi: 10.3389/fonc.2023.1210679

COPYRIGHT

© 2023 Zhanghuang, Long, Yang and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Bilateral adrenal giant medullary lipoma combined with disorders of sex development: a rare case report and literature review

Chenghao Zhanghuang^{1,2†}, Na Long^{3†}, Zhen Yang⁴ and Yucheng Xie^{5,6}*

¹Department of Urology, Kunming Children's Hospital, Yunnan Province Clinical Research Center for Children's Health and Disease, Kunming, China, ²Yunnan Key Laboratory of Children's Major Disease Research, Yunnan Clinical Medical Center for Pediatric Diseases, Kunming Children's Hospital, Kunming, China, ³Special Ward, Kunming Children's Hospital, Yunnan Province Clinical Research Center for Children's Health and Disease, Kunming, China, ⁴Department of Oncology, Yunnan Children Solid Tumor Treatment Center, Kunming, China, ⁶Department of Pathology, Kunming Children's Hospital, Kunming, China, ⁶Department of Pathology, The Second People's Hospital of Yunnan Province, Kunming, China

Bilateral adrenal myelolipoma is rare in clinics and patients with disorders of sex development (DSDs). One case was reported in our center. A 45-year-old patient was admitted to the hospital after discovering a left abdominal mass for more than a year and worsening abdominal pain for 18 days. An imaging examination showed bilateral adrenal masses. Physical examination showed clitoris hypertrophy with patelliform changes, thick and dense pubic hair, normal development of bilateral labia majora without labia minora, and urethral opening. After the relevant preoperative examinations, bilateral adrenal mass resection was performed under general anesthesia. The postoperative pathology confirmed adrenal myelolipoma. The incision healed well without recurrence over 10 years after the operation. Her enlarged clitoris decreased in size. This case report has a detailed diagnosis and treatment process and sufficient examination results. It can provide a reference for diagnosing and treating patients with bilateral adrenal myelolipoma and DSD and reduce the risk of misdiagnosis and mistreatment.

KEYWORDS

adrenal myelolipoma, adrenal gland, disorders of sex development (DSD), diagnosis, pathology

Background

Myelolipoma is a rare non-functional benign tumor formed by the proliferation of mature adipose tissue and hematopoietic components of bone marrow. It was first described histologically by Gierke in 1905 and named myelolipoma by Oberling in 1929 (1). The incidence rate is 0.08%–0.2% (2); clinically, most are asymptomatic, whereas large

tumors will cause waist and abdominal pain or rupture and bleeding, etc. In general, there is no endocrine function, and hypertension can also occur (3). Bilateral giant adrenal myelolipoma is rare. A case of bilateral adrenal giant myelolipoma with disorders of sex development (DSDs) was treated in our center, and the following is reported.

Case report

The patient was 45 years old, and the social gender was female. The patient was admitted to the hospital after discovering a left abdominal mass for over a year and aggravation of abdominal pain for 18 days. In January 2008, the patient developed abdominal pain and discomfort without obvious causes. A left abdominal mass, about 4 cm \times 3.5 cm \times 3 cm in size, was found in the local hospital. In January 2009, the patient touched the left abdomen while bathing and felt that the mass was enlarged and hard, and abdominal pain recurred simultaneously. She was admitted to our hospital with a left abdominal mass of unknown etiology in February 2009. The patient had no fever, night sweats, jaundice, or emaciation. She had no menses since puberty. There was no family history.

Physical examination revealed a temperature of 37.2°C, respiration of 18 beats per minute, pulse of 72 beats per minute, and blood pressure of 120/80 mmHg. The patient had a body weight of 52 kg and a male face with visible whiskers and throat segments and a coarse, deep voice. The axillary hair was thick and dense, the chest was symmetrical without deformity, the breasts were not developed, and a physical examination of the heart and lungs showed no positive signs. The abdomen was soft with no palpable liver. However, a large mass was palpable in the left abdomen with a slightly hard texture and poor mobility, and there was no percussion pain in both renal region. The vulva showed hermaphroditism, thick and dense pubic hair, normal development of bilateral labia majora, no labia minora, hypertrophy of the clitoris like a short penis (4 cm long), no opening at the top, the urethral opening in the vestibule below

the clitoris, and no vagina. On digital rectal examination, there was no palpable uterus or prostate-like tissue, no palpable mass in the pelvic cavity, and no testis-like tissue in the inguinal canal area: scoliosis deformity and free movement of limbs.

Abdominal CT examination showed a huge mixed-density lesion (18 cm \times 15 cm) in the left retroperitoneal space, including many irregular fat density shadows. The upper boundary of the mass was below the diaphragm, and the lower boundary was at the level of the iliac crest. The pancreas, stomach, and spleen were all compressed and displaced anteriorly, and the left kidney was compressed into the pelvis. A mixed-density shadow of 8 cm × 4 cm with clear borders was seen above the right kidney. On enhancement, the parenchymal portion of the left retroperitoneal mass showed variable enhancement that appeared to be encapsulated (Figures 1A-E). Abdominal and pelvic ultrasound showed a mixed echogenic mass in the left adrenal gland and a solid mass in the right upper abdomen. No definite sonograms of the uterus, prostate, or testis were found. Laboratory tests showed white blood cells of 4.39×10^9 /L, neutrophils of 74.7%, lymphocytes decreased by 13.9%, and monocytes increased by 10.5%. The red blood cell count was 5.30×10^{12} /L, and the hemoglobin was 177 g/L. Total bilirubin, direct bilirubin, and indirect bilirubin increased to 30, 11.3, and 18.7 μ mol/L, respectively. Total cholesterol decreased to 2.55 mmol/L, and high-density lipoprotein decreased to 0.95 mmol/L. Other parameters, such as blood glucose and renal function, were normal. Tumor markers such as alpha-fetoprotein, human chorionic gonadotropin, neuron-specific enolase, and carcinoembryonic antigen were negative. Karyotype analysis of the patient's peripheral blood showed that the patient was 46, XX.

The patient underwent open bilateral adrenalectomy under general anesthesia. During the operation, bilateral subcostal transverse incisions were made, the liver and transverse colon were pulled away to expose the retroperitoneal space, and the left retroperitoneal space was dissected after careful mobilization. There was a solid cystic mass (about 24 cm \times 16 cm in size), dark, and hard in texture. The mass was dissected carefully to avoid injury to the renal vein. The huge mass was completely removed, and the other




FIGURE 1

CT and gross specimens of the patient. (A) The left retroperitoneal mass was huge, and the left kidney was compressed and moved down. No enhancement was found in contrast-enhanced scan. (B, C) CT plain scan showed bilateral inhomogeneous density mass. (D, E) Bilateral adrenal enhanced CT findings. (F) Intraoperative gross specimen of a huge mass in the left adrenal gland.

side was about 9 cm \times 5 cm removed. A part of the bilateral mass after complete resection was sent for intraoperative rapid frozen section diagnosis. Intraoperative frozen report: The tumor was derived from adipose tissue and tended to be benign. Lymph node dissection was not performed. After sufficient hemostasis of the operative field, a drainage tube was placed, and the abdominal incision was sutured layer by layer. The intraoperative blood loss was about 500 mL. The operation time was 3 h and 15 min. The operation was uneventful, and anesthesia was stable without a blood transfusion. The patient returned to the ward safely after the operation, and the incision healed well 14 days after the suture was removed. The patient was discharged.

Pathological examination: gross observation: The left side was a yellow-red or dark-red mass, weighing 2.3 kg, measuring 24 cm × 18 $cm \times 10$ cm, with a complete capsule, solid cut surface, and pale yellow fat mixed with reddish-brown (Figure 1F). The right side was a yellow mass measuring 8.5 cm \times 4.3 cm \times 2.8 cm with an intact capsule and fatty cut surface. Microscopic examination showed that the left tumor mainly showed erythroid, granulocytic, and megakaryocytic bone marrow hematopoietic cells without atypia. The erythroid lineage was dominated by mid- and late-stage erythrocytes, whereas the granulocyte was dominated by midand late-young rod and lobulated nuclei. Lymphocytes were scattered or aggregated, and megakaryocytes were scattered, one to three per high-power field. Hemosiderin phagocytosed histiocytes and slight hyperplasia of fibrous tissue were seen locally. A large amount of mature adipose tissue was intermingled. At the edge of the tumor, adrenal globular zone cell clusters of different sizes were seen, and massive hemorrhage was

seen in some areas. On the right side, the tumor mainly comprised mature adipose tissue mixed with bone marrow hematopoietic tissue. Under the tumor capsule, the adrenal zona glomerular cells were rarely compressed. The pathological diagnosis was bilateral adrenal myelolipoma with hemorrhage (the left tumor was huge). The adrenal myelolipoma was considered a benign tumor without secretory function, and no chemotherapy, radiotherapy, or endocrine therapy was given after the operation. The patient was followed up for 14 years and 2 months, and the general condition was good, without discomfort and tumor recurrence.

Discussion

The myelolipoma was composed of a mixture of mature fat and bone marrow in varying proportions. In this case, the multifocal dark red area on the left side was dominated by bone marrow hematopoietic tissue, and a few residual zona glomerulus cells were found under the tumor capsule (Figures 2A, B). The right side was dominated by adipose tissue, and only a little bone marrow hematopoietic tissue was scattered among adipocytes (Figures 2C, D). Myelolipoma is more common in the adrenal gland than in the thoracic cavity, retroperitoneum, presacral area (4), mediastinum, spleen, lung, testis, soft tissue, and other parts. It has been reported that (5) occurs simultaneously in the adrenal gland and the contralateral pelvic cavity, and it is extremely rare that the primary tumor occurs in the liver (6, 7). The most common age of adrenal myelolipoma was 50 to 70, and most patients were adults. The incidence of male and female patients was roughly equal. Most




FIGURE 2

Postoperative pathological and immunohistochemical results. (A, B) The left tumor was composed of fat cells and various hematopoietic cells, and the lower right was the residual adrenal cortex [Immunohistochemistry (HE); (A) 200× and (B) 400×]. (C, D) The right mass was dominated by adipocytes, with scattered small foci of hematopoietic cells (HE; 200×). (E) CD3-positive T lymphocytes (200×). (F) CD15-positive granulocytes (200×). (G) CD20-positive B lymphocytes (200×). (H) CD38-positive plasma cells (200×). (I) CD63-positive monocytes and plate-producing cells (200×). (J) CD117-positive mast cells (200×). (K) CD235a-positive nucleated erythrocytes and mature erythrocytes (200×). (L) Myeloperoxidase (MPO)-positive myeloid cells (200×). tumors are solitary, with a slightly higher incidence on the right side than on the left side and rare on both sides (8). There were no atypia or lip blasts in the adipocytes. Hematopoietic tissue was sparsely or widely distributed, and lymphocytes were scattered or aggregated. Immunohistochemical markers showed granulocytic, erythroid, lymphoid, and megakaryocytic hematopoietic cells at various stages of differentiation (Figures 2E–L).

Differential diagnosis with the following tumors is required: 1. The common type of lipoma has no hematopoietic component, which differs from the location of myelolipoma. It should be noted that some myelolipomas may have fewer hematopoietic components and can be misdiagnosed as lipomas. 2. For welldifferentiated liposarcoma, overlapping with myelolipoma but without hematopoietic components, a careful search for immunohistochemical markers can help. Atypical stromal cells with hyperchromatic chromatin or lip blasts can be found. 3. Myeloid neoplasms, often multiple lesions, accompanied by the liver and spleen enlargement and blood system abnormalities. The tumor showed diffuse infiltration of primitive tumor cells, which were atypical and monomorphic. Immunohistochemical staining showed the absence of normal multilineage hematopoietic components of bone marrow. 4. Extramedullary hematopoiesis, usually in the liver, spleen, and lymph nodes, is associated with lymphohematopoietic disease, and the lesions are often multifocal rather than isolated, well-defined nodules.

Endocrine dysfunction can promote the occurrence of adrenal myelolipoma. Statistics show that about 10% of myelolipoma cases are complicated by endocrine insufficiency, including Cushing syndrome, primary aldosteronism, congenital adrenal hyperplasia (CAH), and hyperparathyroidism (9). CAH is an autosomal negative genetic disease caused by defects in adrenocortical hormone synthase, such as 21-hydroxylase, 17-hydroxylase, or 11-hydroxylase (10). Because of the disorder of the glucocorticoid synthesis pathway, such diseases can lead to obvious hyperandrogenism and hyper-adrenocorticotropic hormone (11). According to statistics, the incidence of adrenal myelolipoma in patients with CAH is significantly higher than that in normal people (about 6%). Its incidence is positively correlated with the level of serum adrenocorticotropic hormone (12). Cases of adrenal myelolipoma with obvious hyperandrogenism have also been reported in the literature (13). Therefore, the pathogenesis of adrenal myelolipoma is closely related to the overexpression of androgen and adrenocorticotropic hormone. The patient was diagnosed with male pseudohermaphroditism, accompanied by amenorrhea and clitoral hypertrophy after puberty, which was considered to be related to the excessive expression of androgens caused by adrenal myelolipoma. The symptoms of clitoral hypertrophy were relieved after surgical resection.

There are many studies on the nature of myelolipomas. Bishop et al. (9) found that most myelolipomas have non-random X chromosome inactivation, suggesting that myelolipomas are of monoclonal origin and belong to genuine tumors. The etiology and pathogenesis of adrenal myelolipoma are still unclear. They may be related to adrenal cortical metaplasia induced by necrosis, infection, stress, and other factors (14–16). Cytogenetic examination of adrenal myelolipoma has been reported with chromosome (3; 21) (q25; 11) translocation, which also suggests a true tumor (17). Some authors point out that adrenal myelolipoma often occurs in endocrine diseases or chronic wasting diseases, which may stimulate the differentiation of adrenal cortical mesenchymal cells into myelocytes or adipocytes (18). At present, the presence of bone tissue in myelolipoma is controversial, and most scholars state that bone tissue is metaplasia.

Myelolipoma is generally asymptomatic, with a volume of less than 5 cm and rarely larger than 10 cm (19). The large volume can cause abdominal distension, pain, or other compression symptoms. There are reports of giant adrenal myelolipoma with a maximum diameter of 15-16 cm (20). In this case, the patient had myelolipoma in both adrenal glands, and the left tumor was huge, with a maximum diameter of 24 cm, accompanied by DSD, manifested as clitoral hypertrophy and no vagina. The principle of myelolipoma treatment is small, and asymptomatic can be conservative follow-up. Yalagachin et al. (21) considered that adrenal myelolipoma with function or diameter ≥ 6 cm should be treated with adrenal tumor resection, and surgical resection of huge tumors can relieve symptoms and prevent complications such as bleeding and rupture. In the past, open surgery was the main clinical operation for giant myelolipoma. However, with the development of laparoscopic technology, laparoscopic adrenalectomy has become the first choice for adults. Of note, is the transabdominal or retroperitoneal approach more advantageous? It is still controversial (22). In recent years, good results of robotic surgical treatment have also been reported (23). In addition, studies have shown that minimally invasive surgery can effectively reduce surgical site infection caused by open surgery so that patients can obtain better perioperative outcomes (24).

Conclusion

In conclusion, myelolipoma is rare in clinical practice, and it is rare to present a huge mass in both adrenal glands with DSD. Adrenal myelolipoma is a benign non-secretory tumor. The tumor was named for the presence of mature adipocytes and bone marrow cells. The disease may result from abnormal cortical reticular endothelial cell metaplasia development or aberrant embryonic residues. However, patients with adrenal myelolipoma that produce compression symptoms such as hypertension need surgical resection of the tumor to relieve the symptoms. Adrenal myelolipoma is considered a benign tumor without secretory function, and postoperative chemoradiotherapy and endocrine therapy are not needed. Patients with adrenal myelolipoma complicated with disorders of sexual development can be followed up after resection of adrenal myelolipoma before oculoplastic surgery, and some patients with disorders of sexual development can spontaneously relieve the abnormal manifestations of external genitalia.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethical Committee of Kunming Children's Hospital (2022-12-001-K01). This study is by the relevant guidelines and regulations. The data in this study were obtained from this patient and his legal guardian. Written informed consent was obtained from the patient's parents.

Author contributions

CZ designed the study. CZ, NL, and ZY collected and analyzed the data. CZ drafted the initial manuscript. CZ revised the article critically. CZ, ZY, NL, BY, and YX reviewed and edited the article. NL and CZ are co-first authors. All authors approved the final manuscript.

Funding

This study was supported by Yunnan Education Department of Science Research Fund (Nos. 2023 J0295 and 2020J0228), Kunming City Health Science and Technology Talent "1000" training Project

References

1. Meaglia JP, Schmidt JD. Natural history of an adrenal myelolipoma. J Urol (1992) 147(4):1089–90. doi: 10.1016/S0022-5347(17)37482-7

2. Hasan M, Siddiqui F, Al-Ajmi M. FNA diagnosis of adrenal myelolipoma: a rare entity. *Diagn Cytopathol* (2008) 36(12):925–6. doi: 10.1002/dc.20941

3. Jakka N, Venkateshwarlu J, Satyavani N, Neelaveni K, Ramesh J. Functioning adrenal myelolipoma: A rare cause of hypertension. *Indian J Endocrinol Metab* (2013) 17(Suppl 1):S249–51. doi: 10.4103/2230-8210.119588

4. Rizzo G, Coramusi C, Pietricola G, Sionne F, Castri F, Pafundi DP, et al. Laparoscopic approach for a presacral myelolipoma resembling a liposarcoma. J Surg Case Rep (2018) 2018(7):rjy156. doi: 10.1093/jscr/rjy156

5. Wadood DQ, Qureshi DSA, Singh DP, Freedman DJ. A rare case of co-existing adrenal and pelvic myelolipomas. *Radiol Case Rep* (2018) 13(5):999–1002. doi: 10.1016/j.radcr.2018.07.008

6. Gallo M, Mineur L, Emptas H, Costes V, Ramos J. Myélolipome hépatique : une entité rare, à propos d'un cas et revue de la littérature [Hepatic myelolipoma: A rare entity, case report and review of the literature]. *Ann Pathol* (2017) 37(5):415–9. doi: 10.1016/j.annpat.2017.06.010

7. Menozzi G, Maccabruni V, Marini G, Froio E, Garlassi E. Contrast-enhanced ultrasound (CEUS) appearance of hepatic myelolipoma. *J Ultrasound* (2014) 19(1):61–5. doi: 10.1007/s40477-014-0137-y

8. Zieker D, Königsrainer I, Miller S, Vogel U, Sotlar K, Steurer W, et al. Simultaneous adrenal and extra-adrenal myelolipoma - an uncommon incident: case report and review of the literature. *World J Surg Oncol* (2008) 6:72. doi: 10.1186/1477-7819-6-72

9. Bishop E, Eble JN, Cheng L, Wang M, Chase DR, Orazi A, et al. Adrenal myelolipomas show nonrandom X-chromosome inactivation in hematopoietic elements and fat: support for a clonal origin of myelolipomas. *Am J Surg Pathol* (2006) 30(7):838–43. doi: 10.1097/01.pas.0000202044.05333.17

10. Fowler MR, Williams RB, Alba JM, Byrd CR. Extra-adrenal myelolipomas compared with extramedullary hematopoietic tumors: a case of presacral myelolipoma. *Am J Surg Pathol* (1982) 6(4):363–74. doi: 10.1097/00000478-198206000-00009

[No. 2020-SW (Reserve)-112], Kunming Health and Health Commission Health Research Project (No. 2020-0201-001), Kunming Medical Joint Project of Yunnan Science and Technology Department (No. 202001 AY070001-271), Department of Science and Technology of Yunnan province Kunming medicine Joint Special project (No.202301AY070001-108), and Open Research Fund of Clinical Research Center for Children's Health and Diseases of Yunnan Province (No.2022-ETYY-YJ-03). The funding bodies played no role in the study's design and collection, data analysis and interpretation, and manuscript writing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

11. Shalaby M, Chandran H, Elford S, Kirk J, McCarthy L. Recommendations of patients and families of girls with 46XX congenital adrenal hyperplasia in the United Kingdom regarding the timing of surgery. *Pediatr Surg Int* (2021) 37(1):137–43. doi: 10.1007/s00383-020-04780-3

12. Nermoen I, Rørvik J, Holmedal SH, Hykkerud DL, Fougner KJ, Svartberg J, et al. High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency. *Clin Endocrinol (Oxf)* (2011) 75(6):753–9. doi: 10.1111/j.1365-2265.2011.04151.x

13. Su HC, Huang X, Dai J, Sun FK. Adrenal myelolipoma associated with hyperandrogenemia. Int J Urol (2012) 19(11):1026–8. doi: 10.1111/j.1442-2042.2012.03100.x

14. Calissendorff J, Juhlin CC, Sundin A, Bancos I, Falhammar H. Adrenal myelolipomas. *Lancet Diabetes Endocrinol* (2021) 9(11):767–75. doi: 10.1016/S2213-8587(21)00178-9

15. Alvarez JF, Goldstein L, Samreen N, Beegle R, Carter C, Shaw A, et al. Giant adrenal myelolipoma. J Gastrointest Surg (2014) 18(9):1716–8. doi: 10.1007/s11605-014-2553-x

16. Wrightson WR, Hahm TX, Hutchinson JR, Cheadle W. Bilateral giant adrenal myelolipomas: a case report. *Am Surg* (2002) 68(6):588–9. doi: 10.1177/000313480206800615

17. Chang KC, Chen PI, Huang ZH, Lin YM, Kuo PL. Adrenal myelolipoma with translocation (3;21)(q25;p11). *Cancer Genet Cytogenet* (2002) 134(1):77-80. doi: 10.1016/S0165-4608(01)00592-1

18. Luo I, Wang T, Cheng M, Ge X, Song S, Zhu G, et al. Rare benign liver tumors that require differentiation from hepatocellular carcinoma: focus on diagnosis and treatment. *J Cancer Res Clin Oncol* (2023) 149(7):2843–54. doi: 10.1007/s00432-022-04169-w

19. Gupta P, Mondal S, Datta C, Pal DK. Bilateral giant adrenal myelolipoma: A rare scenario. *Indian J Pathol Microbiol* (2022) 65(3):689–91. doi: 10.4103/ ijpm.ijpm_182_21

20. Posses SP, Prado BC, Bechara GR, Puppim AR, Carli CRS, MIranda MML. Giant bilateral adrenal myelolipoma:Case presentation and a brief literature review. *Urol Case Rep* (2018) 18:67–9. doi: 10.1016/j.eucr.2018.03.008

21. Yalagachin GH, Bhat BK. Adrenal incidentaloma does it require surgical treatment? Case report and review of literature. *Int J Surg Case Rep* (2013) 4(2):192–4. doi: 10.1016/j.ijscr.2012.09.014

22. Arezzo A, Bullano A, Cochetti G, Cirocchi R, Randolph J, Mearini E, et al. Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for adrenal tumours in adults. Cochrane Database Syst Rev (2018) 12(12):CD011668. doi: 10.1002/14651858.CD011668.pub2

23. Cochetti G, Paladini A, Boni A, Silvi E, Tiezzi A, De Vermandois JAR, et al. Robotic treatment of giant adrenal myelolipoma: A case report and review of the literature. *Mol Clin Oncol* (2019) 10(5):492–6. doi: 10.3892/mco.2019.1823

24. de Vermandois JAR, Cochetti G, Zingaro MD, Santoro A, Panciarola M, Boni A, et al. Evaluation of surgical site infection in mini-invasive urological surgery. *Open Med* (*Wars*) (2019) 14:711–8. doi: 10.1515/med-2019-0081